Stifel Nicolaus analyst Rick Wise has maintained their bullish stance on BSX stock, giving a Buy rating yesterday.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Rick Wise has given his Buy rating due to a combination of factors tied to Boston Scientific’s strengthening electrophysiology franchise. He highlights the FDA approval of the Farapoint focal pulsed-field ablation catheter, which, despite a modest delay, expands the company’s already leading PFA offering anchored by the Farawave system. Farapoint’s design for focal and linear lesion creation, particularly in cavotricuspid isthmus ablation and persistent or repeat atrial fibrillation procedures, addresses a large and recurring subset of ablation volumes. The catheter’s integration with the Faraview mapping software reinforces Boston Scientific’s ability to offer a more complete, technology-driven ecosystem to electrophysiologists.
Wise also underscores that the addition of Farapoint can enhance revenue per procedure by allowing Boston Scientific to capture incremental dollars in PFA cases where physicians would otherwise open a separate RF catheter. This mirrors usage patterns reported by major RF competitors, suggesting a tangible share and wallet opportunity. In his view, the Farapoint approval is not just a single-product event but a signal of Boston Scientific’s ongoing innovation and commitment to the electrophysiology space. Taken together, the product expansion, ecosystem integration, and revenue uplift potential support his positive stance on the stock and underpin his Buy recommendation.
In another report released yesterday, Bernstein also maintained a Buy rating on the stock with a $130.00 price target.